Hepatitis Clinical Trials

Showing 1761-1780 of 2,113 trials

Hepatitis B Virus HBeAg-negative Genotype D Patients and Hepatocellular Carcinoma

NCT02025842

To evaluate the impact of liver fibrosis and other variables \[e.g., age, sex, virological response (VR), and previous resistance to nucleoside/nucleotide analogue (NUC) therapy\] on Hepatocellular carcinoma incidence in an Italian population of genotype D HBeAg-negative CHB patients treated with long-term NUC therapy.

Hepatocellular CarcinomaHepatitis B

Azienda Ospedaliera San Camillo Forlanini306 participantsStarted Jan 2000

COMPLETEDPhase 1

Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults

NCT00557583

The study will evaluate the safety and pharmacokinetics of single doses of VBY-376 in healthy subjects.

Chronic Hepatitis C Infection

Virobay Inc.48 participantsStarted Nov 2007

Madison, Wisconsin, United States

COMPLETEDNA

Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E

NCT01813487

The purpose of this study is to examine the immunogenicity and efficacy of HBsAg Vaccine in combination with Entecavir in patients who have been treated with HB110E HBV DNA vaccine.

Chronic Hepatitis B

Genexine, Inc.6 participantsStarted Feb 2013

Seoul, South Korea

COMPLETEDPhase 4

A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children

NCT01349829

This is a study to test whether vaccination with HAVpur Junior against hepatitis A provides protection that is non-inferior to the protection afforded by vaccination with Havrix 720 Junior.

Hepatitis A

Crucell Holland BV251 participantsStarted Mar 2010

Indore, Madhya Pradesh, India • Thane, Maharashtra, India • Ludhiana, Punjab, India

Hepatitis B Virus HBeAg-negative Genotype D Patients and Hepatocellular Carcinoma

Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults

Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E

A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children

Related Searches

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

Prevention of Hepatitis B Virus Mother-to-child Transmission by Serovaccination.

Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3

Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease

Impact of Hepatitis C Virus Variability on Steatosis

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

The Follow-up Study of Chronic Hepatitis B Patients With Liver Cirrhosis Receiving Anti-HBV Therapy

Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy

A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism